The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Treating smoldering myeloma and the importance of improving patient selection
Sigurdur Kristinsson, MD, PhD, University of Iceland, Reykjavík, Iceland, outlines the treatment approaches used in patients in the iStopMM trial (NCT03327597) who were identified as having smoldering multiple myeloma (SMM). Prof. Kristinsson highlights that individuals on this trial who were not treated also did not experience SMM progression, underscoring the importance of carefully selecting patients for treatment to avoid unnecessary intervention. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
